Spreadsheet: 03f83b53-cac8-4856-8d0c-68112cd29b09
Sheet: Sheet1

ID | Age | Malignancy | Group | PSA [ng/ml] | Free PSA [%] | Tumor-stage (pathol) | Gleason-score (pathol) | 1st. Expression screen | ID in                                      Schlomm and [NAME] et al. 2009 (1) | Group in                        Schlomm and [NAME] et al. 2009 (1)
BBN-12 | 58 | Tumor negative | TN-nPSA-group | 0.2 | 30 |  |  | yes | 39 | Healthy
BB-N13 | 56 | Tumor negative | TN-nPSA-group | 0.35 | 25.71 |  |  | yes | 40 | Healthy
BB-N15 | 57 | Tumor negative | TN-nPSA-group | 0.49 | 30.61 |  |  | yes | 42 | Healthy
BB-N16 | 54 | Tumor negative | TN-nPSA-group |  |  |  |  | yes
BB-N17 | 64 | Tumor negative | TN-nPSA-group | 0.75 | 24 |  |  | yes | 43 | Healthy
BB-N18 | 48 | Tumor negative | TN-nPSA-group | 0.84 | 29.76 |  |  | yes | 44 | Healthy
BB-N19 | 50 | Tumor negative | TN-nPSA-group | 0.8 | 38.75 |  |  | yes | 45 | Healthy
BBN-32R | 57 | Tumor negative | TN-nPSA-group | 1.12 | 31.25 |  |  | yes
BBN-33L | 55 | Tumor negative | TN-nPSA-group | 0.81 | 24.69 |  |  | yes
BBN-34R | 56 | Tumor negative | TN-nPSA-group | 0.42 | 35.71 |  |  | yes
BBN-36L | 57 | Tumor negative | TN-nPSA-group | 0.82 | 21.95 |  |  | yes
BBN-37L | 55 | Tumor negative | TN-nPSA-group | 0.83 | 24.1 |  |  | yes
BBN-38R | 65 | Tumor negative | TN-nPSA-group | 0.5 |  |  |  | yes
BBN-39L | 63 | Tumor negative | TN-nPSA-group | 0.69 | 34.78 |  |  | yes
[NAME] | 51 | Tumor negative | TN-nPSA-group | 0.45 | 37.87 |  |  | yes | 31 | Healthy
[NAME] | 64 | Tumor negative | TN-nPSA-group | 0.86 | 27.91 |  |  | yes
BBN-41L | 55 | Tumor negative | TN-nPSA-group | 1.1 | 25.45 |  |  | yes
SBN-109L | 80 | Tumor negative | TN-hPSA-group | 20.54 | 12.37 |  |  |  | 57 | A
SBN-112L | 64 | Tumor negative | TN-hPSA-group |  |  |  |  |  | 58 | A
SBN-125R | 53 | Tumor negative | TN-hPSA-group | 6.04 | 10.6 |  |  |  | 59 | A
SBN-181R | 52 | Tumor negative | TN-hPSA-group | 8.15 | 18.53 |  |  |  | 62 | A
SBN-192L | 66 | Tumor negative | TN-hPSA-group | 6.28 | 30.89 |  |  |  | 63 | A
SBN-198L | 65 | Tumor negative | TN-hPSA-group | 13.39 | 29.42 |  |  |  | 64 | A
SBN-203R | 65 | Tumor negative | TN-hPSA-group | 3.05 | 31.15 |  |  |  | 66 | A
SBN-206R | 77 | Tumor negative | TN-hPSA-group |  |  |  |  |  | 68 | A
SBN-51 | 71 | Tumor negative | TN-hPSA-group | 3.05 | 9.18 |  |  |  | 69 | A
SBN-66 | 70 | Tumor negative | TN-hPSA-group | 7.52 | 23.94 |  |  |  | 70 | A
SBN-74 | 71 | Tumor negative | TN-hPSA-group | 10.46 | 18.36 |  |  |  | 71 | A
SBN-77 | 60 | Tumor negative | TN-hPSA-group | 6.4 | 19.69 |  |  |  | 72 | A
SBN-79 | 60 | Tumor negative | TN-hPSA-group | 6.36 | 17.45 |  |  |  | 73 | A
SBN-91R | 57 | Tumor negative | TN-hPSA-group | 6.48 | 16.67 |  |  |  | 74 | A
CBN-114R | 64 | Tumor positive | TP-group |  |  | pT2c | 3+4 |  | 109 | C
CBN-117R | 65 | Tumor positive | TP-group | 6.02 | 10.3 | pT3a | 3+4 |  | 111 | C
CBN-128R | 60 | Tumor positive | TP-group |  |  | pT2c | 3+4 |  | 116 | C
CBN-140R | 52 | Tumor positive | TP-group | 8.77 | 8.32 | pT2c | 3+4 |  | 117 | C
CBN-143L | ? | Tumor positive | TP-group | 3.34 | 15.27 | pT3a | 3+3 |  | 118 | C
CBN-145L | 57 | Tumor positive | TP-group | 5.46 | 20.88 | pT2c | 3+3 |  | 119 | C
CBN-148L | 53 | Tumor positive | TP-group | 3.04 | 15.46 | pT2c | 3+4 |  | 122 | C
CBN-149R | 62 | Tumor positive | TP-group | 9.11 | 9.77 | pT2c | 3+3 |  | 123 | C
CBN-152R | 63 | Tumor positive | TP-group | 9.38 | 6.18 | pT2c | 3+3 |  | 124 | C
CBN-154R | 66 | Tumor positive | TP-group | 12.27 | 14.83 | pT3b | 3+4 |  | 126 | C
CBN-155R | 57 | Tumor positive | TP-group | 24.17 | 28.71 | pT2c | 3+3 |  | 127 | C
CBN-156R | 66 | Tumor positive | TP-group | 3.7 | 12.16 | pT2c | 3+4 |  | 128 | C
CBN-157R | 65 | Tumor positive | TP-group | 6.2 | 4.52 | pT2c | 3+4 |  | 129 | C
CBN-161L | 54 | Tumor positive | TP-group | 9.53 | 5.14 | pT2a | 4+3 |  | 130 | C
CBN-162R | 58 | Tumor positive | TP-group | 17.98 | 13.24 | pT3a | 4+3 |  | 131 | C
CBN-166L | 62 | Tumor positive | TP-group | 4.48 | 7.81 | pT2a | 3+4 |  | 133 | C
CBN-171R | 58 | Tumor positive | TP-group | 6.48 | 6.48 | pT2c | 3+4 |  | 136 | C
CBN-175R | 65 | Tumor positive | TP-group | 16.71 | 6.1 | pT2a | 4+4 |  | 139 | C
CBN-178L | 54 | Tumor positive | TP-group | 7.31 | 7.8 | pT2c | 3+4 |  | 141 | C
CBN-40R | 64 | Tumor positive | TP-group | 18.22 | 9.22 |  |  |  | 142 | C
CBN-46R | 64 | Tumor positive | TP-group | 7.97 | 7.28 | pT2c | 4+3 |  | 143 | C
CBN-47L | 66 | Tumor positive | TP-group |  |  | pT2a | 3+4 |  | 144 | C
CBN-53L | 69 | Tumor positive | TP-group | 4.68 | 22.86 | pT3b | 3+4 |  | 145 | C
CBN-59L | 62 | Tumor positive | TP-group | 7.85 | 6.62 | pT2c | 3+4 |  | 146 | C
CBN-65L | 64 | Tumor positive | TP-group | 5.75 | 9.91 | pT2c | 3+3 |  | 147 | C
CBN-73R | 47 | Tumor positive | TP-group |  |  | pT2c | 3+4 |  | 149 | C
CBN-74R | 65 | Tumor positive | TP-group | 4.02 | 16.92 | pT2c | 3+4 |  | 150 | C
[NAME] | 62 | Tumor positive | TP-group | 9.82 | 9.06 | pT2c | 3+4 |  | 151 | C
CBN-86L | 55 | Tumor positive | TP-group | 8.39 | 7.63 | pT2c | 3+3 |  | 152 | C
CBN-87R | 59 | Tumor positive | TP-group | 10.62 | 10.73 | pT2c | 3+4 |  | 153 | C
CBN-88L | 66 | Tumor positive | TP-group | 13.99 | 14.51 | pT2c | 3+4 |  | 154 | C
supplemental table 1
Clinico-pathological data of the individuals enclosed in the study and assignment to the groups in this study compared to our previous study on mRNA-patterns in normal tumor adjacent prostate tissues (1).